FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to medicine and pharmaceutics, namely to use of a composition containing a therapeutically effective amount of alpha-1-antitrypsin protein (AAT) and at least one pharmaceutical carrier for treating and/or preventing Charcot-Marie-Tooth disease.
EFFECT: treatment or prevention of Charcot-Marie-Tooth disease.
4 cl, 19 dwg, 22 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT AND/OR PREVENTION OF DISEASE OR SYNDROME ASSOCIATED WITH VIRAL INFECTION | 2021 |
|
RU2823437C2 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| METHOD FOR EARLY DETECTION OF NEUROLOGICAL DISORDERS IN PATIENTS WITH COVID-19 | 2021 |
|
RU2779562C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING POLYNUCLEOTIDES, AND USE THEREOF FOR PREVENTING OR TREATING COVID-19 | 2021 |
|
RU2824489C1 |
| BISPECIFIC MONOCLONAL ANTIBODY AGAINST SARS-COV-2 | 2022 |
|
RU2791749C1 |
| TREATMENT OF CORONAVIRUS INFECTION | 2021 |
|
RU2837859C1 |
| ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
| METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
| THERAPEUTIC AGENT AGAINST CORONAVIRUS INCLUDING AN ELAEOCARPUS SYLVESTRIS EXTRACT | 2021 |
|
RU2780346C1 |
| PIV5-BASED COVID-19 VACCINE | 2021 |
|
RU2838536C1 |
